Serum 25-hydroxyvitamin D levels in restless legs syndrome patients

Sleep Medicine

Volumn 13, Issue 7, 2012, Pages 953-957

  Balaban, Hatice ^a   Yildiz, özlem Kayim ^a   Çil, Gülsüm ^a   Şentürk, Ilteriş Ahmet ^a   Erselcan, Taner ^a   Bolayir, Ertuĝrul ^a   Topaktaş, Suat ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Aetiology; Deficiency; Dopamine; Restless legs syndrome; Sleep disturbance; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD ANALYSIS; BODY MASS; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; FEMALE; HUMAN; MALE; METABOLITE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SEX DIFFERENCE; VITAMIN BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; RESTLESS LEGS SYNDROME; SEX FACTORS; VITAMIN D;

EID: 84863863686     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2012.04.009     Document Type: Article

References (44)

1. Aritake-Okada S., Nakao T., Komada Y., Asaoka S., Sakuta K., Esaki S., et al. Prevalence and clinical characteristics of restless legs syndrome in chronic kidney disease patients. Sleep Med 2011, 12(10):1031-1033.
2. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4(2):101-119.
3. Berger K., Kurth T. RLS epidemiology, frequencies, risk factors and methods in population studies. Mov Disord 2007, 22(18):420-423.
4. Allen R.P., Walters A.S., Montplaisir J., Hening W., Myers A., Bell T.J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165(11):1286-1292.
5. Allen R.P., Bharmal M., Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011, 26(1):114-120.
6. Brindani F., Vitetta F., Gemignani F. Restless legs syndrome: differential diagnosis and management with pramipexole. Clin Interv Aging 2009, 4:305-313.
7. Prakash S, Bhanvadia RJ, Shah ND. Restless legs syndrome with carbamazepine-induced osteomalacia: causal or casual association. Gen Hosp Psychiatry 2010;32(2):228.e1-3.
8. Bayard S., Yu H., Langenier M.C., Carlander B., Dauvilliers Y. Decision making in restless legs syndrome. Mov Disord 2010, 25(15):2634-2640.
9. Allen R.P., Barker P.B., Wehrl F., Song H.K., Earley C.J. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001, 56(2):263-265.
10. Connor J.R., Wang X.S., Allen R.P., Beard J.L., Wiesinger J.A., Felt B.T., et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 2009, 132(9):2403-2412.
11. Connor J.R., Ponnuru P., Wang X.S., Patton S.M., Allen R.P., Earley C.J. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011, 134(4):959-968.
12. Peeyush K.T., Savitha B., Sherin A., Anju T.R., Jes P., Paulose C.S. Cholinergic, dopaminergic and insulin receptors gene expression in the cerebellum of streptozotocin-induced diabetic rats: functional regulation with vitamin D3 supplementation. Pharmacol Biochem Behav 2010, 95(2):216-222.
13. Knekt P., Kilkkinen A., Rissanen H., Marniemi J., Sääksjärvi K., Heliövaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol 2010, 67(7):808-811.
14. Cherniack E.P., Troen B.R., Florez H.J., Roos B.A., Levis S. Some new food for thought: the role of vitamin D in the mental health of older adults. Curr Psychiatry Rep 2009, 11(1):12-19.
15. Wang J.Y., Wu J.N., Cherng T.L., Hoffer B.J., Chen H.H., Borlongan C.V., et al. Vitamin D3 attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res 2001, 904:67-75.
16. Ibi M., Sawada H., Nakanishi M., Kume T., Katsuki H., Kaneko S., et al. Protective effects of 1,25-(OH)2D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 2001, 40:761-771.
17. Walters A.S. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995, 10:634-642.
18. Walters A.S., LeBrocq C., Dhar A. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003, 4:121-132.
19. Salman S.M. Restless legs syndrome in patients on hemodialysis. Saudi J Kidney Dis Transpl 2011, 22(2):368-372.
20. Uglane M.T., Westad S., Backe B. Restless legs syndrome in pregnancy is a frequent disorder with a good prognosis. Acta Obstet Gynecol Scand 2011, 90(9):1046-1048.
21. Walters A.S., Rye D.B. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 2009, 32(5):589-597.
22. Winkelmann J., Muller-Myhsok B., Wittchen H.U., Hock B., Prager M., Pfister H., et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol 2002, 52:297-302.
23. Tison F., Crochard A., Léger D., Bouée S., Lainey E., El Hasnaoui A. Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 2005, 65:239-246.
24. Cervenka S., Pålhagen S.E., Comley R.A., Panagiotidis G., Cselényi Z., Matthews J.C., et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006, 129:2017-2028.
25. Turjanski N., Lees A.J., Brooks D.J. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999, 52:932-937.
26. Ruottinen H.M., Partinen M., Hublin C., Bergman J., Haaparanta M., Solin O., et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000, 54:502-504.
27. Trotti L.M., Bhadriraju S., Rye D.B. An update on the pathophysiology and genetics of restless legs syndrome. Curr Neurol Neurosci Rep 2008, 8(4):281-287.
28. Allen R.P., Earley C.J. The role of iron in restless legs syndrome. Mov Disord 2007, 22(18):440-448.
29. Zucconi M., Manconi M. Sleep and quality of life in restless legs syndrome. Sleep and quality of life in clinical medicine 2008, 101-106. Humana Press, Totowa, NJ. J.C. Verster, S.R. Pandi-Perumal, D. Streiner (Eds.).
30. Manconi M., Ferri R., Zucconi M., Clemens S., Giarolli L., Bottasini V., et al. Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome. Neurology 2011, 77(2):110-117.
31. Holick M.F., Vitamin D. A millennium perspective. J Cell Biochem 2003, 88:296-307.
32. Meguro S., Tomita M., Katsuki T., Kato K., Oh H., Ainai A., et al. Plasma 25-hydroxyvitamin d is independently associated with hemoglobin concentration in male subjects with type 2 diabetes mellitus. Int J Endocrinol 2011, 2011:362981.
33. Abou-Raya S., Helmii M., Abou-Raya A. Bone and mineral metabolism in older adults with Parkinson's disease. Age Ageing 2009, 38(6):675-680.
34. Newmark H.L., Newmark J. Vitamin D and Parkinson's disease - a hypothesis. Mov Disord 2007, 22(4):461-468.
35. Evatt M.L., Delong M.R., Khazai N., Rosen A., Triche S., Tangpricha V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008, 65(10):1348-1352.
36. Baksi S.N., Hughes M.J. Chronic vitamin D deficiency in the weanling rat alters catecholamine metabolism in the cortex. Brain Res 1982, 242(2):387-390.
37. Heldenberg D., Tenenbaum G., Weisman Y. Effect of iron on serum 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D concentrations. Am J Clin Nutr 1992, 56(3):533-536.
38. Masuhara T., Migicovsky B.B. Vitamin D and the intestinal absorption of iron and cobalt. J Nutr 1963, 80:332-336.
39. Garcion E., Sindji L., Leblondel G., Brachet P., Darcy F. 1,25-dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem 1999, 73:859-866.
40. Brewer L.D., Thibault V., Chen K.C., Langub M.C., Landfield P.W., Porter N.M. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 2001, 21:98-108.
41. Neveu I., Naveilhan P., Baudet C., Brachet P., Metsis M. 1,25-dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. Neuroreport 1994, 6:124-126.
42. Buell J.S., Dawson-Hughes B., Scott T.M., Weiner D.E., Dallal G.E., Qui W.Q., et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010, 74(1):18-26.
43. Garcion E., Wion-Barbot N., Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002, 13:100-105.
44. Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005, 29(1):21-30.